André T et al. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): A randomised, open-label phase 3 study. Lancet Gastroenterol Hepatol 2023;8(2):133-44. Abstract
Bekaii-Saab TS et al. MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—trial in progress. Gastrointestinal Cancers Symposium 2023;Abstract TPS261.
Bekaii-Saab TS et al. Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes. ESMO 2022;Abstract 376P.
Catenacci DV et al. MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress. ESMO 2021;Abstract 1434TiP.
Cercek A et al. HER2 testing in colorectal cancer: Concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER Trial. Gastrointestinal Cancers Symposium 2023;Abstract 198.
Ciombor KK et al. BRAF-mutated advanced colorectal cancer: A rapidly changing therapeutic landscape. J Clin Oncol 2022;40(24):2706-15. Abstract
Cohen SA et al. Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer. ESMO 2022;Abstract 319MO.
Diaz LA Jr et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2022;23(5):659-70. Abstract
Kotani D et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 2023;29(1):127-34. Abstract
Kuboki Y et al. Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase 1b full expansion cohort. ESMO 2022;Abstract 315O.
Morris VK et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 2022;41(3):678-700. Abstract
Morris VK, Strickler JH. Use of circulating cell-free DNA to guide precision medicine in patients with colorectal cancer. Annu Rev Med 2021;72:399-413. Abstract
Park H et al. Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (Trial in Progress). Gastrointestinal Cancers Symposium 2022;Abstract TPS376.
Raghav KPS et al. Assessment of HER2 (ERBB2) amplification (HER2amp) using blood based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC). ASCO 2021;Abstract 3589.
Stickler JH et al. Diagnosis and treatment of ERBB2-positive metastatic colorectal cancer: A review. JAMA Oncol 2022;8(5):760-9. Abstract
Stickler J et al. Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC. ESMO 2022;Abstract LBA-2.
Tabernero J et al. Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 SUNLIGHT study. Gastrointestinal Cancers Symposium 2023;Abstract 4.
Tabernero J et al. BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAF V600E metastatic colorectal cancer (mCRC). ESMO 2022;Abstract LBA26.
Tabernero J et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 2021;39(4):273-84. Abstract
Tie J et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022;386(24):2261-72. Abstract
Van Cutsem E et al. ANCHOR CRC: A single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. ESMO 2021;Abstract O-10.
Wu C et al. Tucatinib plus trastuzumab in patients (pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER. ESMO 2022;Abstract 361P.
Yoshino T et al. Panitumumab (pan) plus mFOLFOX6 versus bevacizumab (bev) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. ASCO 2022;Abstract LBA1.